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Abstract  1 
Background: Meningococcal conjugate vaccines protect individuals directly, but may also confer 2 
herd protection by interrupting carriage transmission. This Phase III observer-blind, 3 
randomised, controlled study evaluated the effects of meningococcal quadrivalent 4 
glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal 5 
carriage rates in 18-24 year-old adults. 6 
Methods: University students from ten sites in England were randomised (1:1:1, block size of 7 
three) to receive two doses one month apart of Japanese Encephalitis vaccine (controls), 8 
4CMenB, or one dose of MenACWY-CRM then placebo. Participants and outcome-assessors 9 
were blinded to treatment arm. Meningococci were isolated from oropharyngeal swabs 10 
collected before vaccination and at five scheduled intervals over one year. Primary analyses 11 
were cross-sectional carriage one month after each vaccine course; secondary analyses 12 
included comparisons of carriage at any time point after primary analysis until study 13 
termination. Reactogenicity and adverse events were monitored throughout the study. 14 
Findings: 2954 subjects were randomised (control, n=987; 4CMenB, n=979; MenACWY-CRM, 15 
n=988); approximately one-third of each group was positive for meningococcal carriage at 16 
study entry. By one month, there was no significant difference in carriage between controls and 17 
ϰCMeŶB ;Odds ‘atios ;O‘Ϳ, ϭ·Ϯ [ϵϱ%CI: Ϭ·ϴ−ϭ·ϳ]Ϳ oƌ MeŶACWY-CRM (OR, 0·9 [95%CI: 0·6–1·3]) 18 
groups. From three months after dose two, 4CMenB vaccination resulted in significantly lower 19 
carriage of any meningococcal strain (18·2% [95%CI: 3·4–30·8] carriage reduction) and capsular 20 
groups BCWY (26·6% [95%CI: 10·5–39·9] carriage reduction) compared to control vaccination. 21 
Significantly lower carriage rates were also observed in the MenACWY-CRM group compared 1 
with controls: 39·0% [95%CI: 17·3-55·0] and 36·2% [95%CI: 15·6-51·7] carriage reduction for 2 
serogroups Y and CWY, respectively. Study vaccines were generally well tolerated, with 3 
elevated rates of transient local injection pain, and myalgia, in the 4CMenB group. No safety 4 
concerns were identified. 5 
Interpretation: MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates 6 
over 12 months post-vaccination and, therefore, may affect transmission where widely 7 
implemented. [ClinicalTrials.gov, NCT01214850] 8 
Funding Source: Novartis Vaccines (NVS) 9 
Keywords: Meningococcal, carriage, vaccine, serogroup B, conjugate, herd protection 10 
Introduction 1 
It is estimated that there are 0·5–1·2 million episodes of meningococcal disease every year 2 
causing 50,000–135,000 deaths worldwide.1,2 Neisseria meningitidis colonises the nasopharynx 3 
and is transmitted via large-droplet spread. Asymptomatic carriage is highest among 4 
adolescents, associated with social behaviours such as bedroom-sharing, smoking, kissing, and 5 
attending bars and clubs.
3–6
 The most important disease-associated serogroups are A, B, C, W, 6 
and Y, with X being a recent concern in Africa.
7
 Post-implementation analyses of population-7 
scale vaccination programmes reveal that meningococcal serogroup C conjugate (MCC) 8 
vaccines provide benefit not only by direct protection of vaccinated individuals, but more 9 
importantly also through the interruption of transmission (i.e., herd protection),
8–10
 a factor 10 
that enhances public health impact and cost-effectiveness.
11
  11 
In addition to quadrivalent glycoconjugate vaccines against serogroups A, C, W, and Y such as 12 
MenACWY-CRM (Menveo®, NVS, Siena, Italy), a multi-component serogroup B meningococcal 13 
vaccine, 4CMenB (Bexsero®, NVS, Siena, Italy) has recently been licensed in the European 14 
Union, Australia and Canada. 4CMenB contains Neisseria Heparin Binding Antigen (subvariant 15 
1.2) fused with accessory protein 953, Neisserial adhesin A (subvariant 3.1), factor H binding 16 
protein (subvariant 1.1) fused with accessory protein 936, and the outer membrane vesicle 17 
(OMV) from N meningitidis strain NZ98/254 (OMV NZ) derived from the MeNZB vaccine.
12,13
  18 
We report the findings from a study conducted to evaluate the effect of 4CMenB and 19 
MenACWY-CRM vaccination on meningococcal carriage rates in university students in England. 20 
Methods  1 
This was a randomised, observer-blind, controlled Phase III study at ten study centres in 2 
England, conducted in accordance with the provisions of the Declaration of Helsinki (1996) and 3 
the International Conference on Harmonization Guidelines for Good Clinical Practice. The 4 
National Research Ethics Service approved the study protocol. All participants gave informed 5 
consent. This trial is registered with ClinicalTrials.gov, number NCT01214850.  6 
Study population 7 
Eligible participants were healthy males and females attending university, aged 18–24 years, 8 
who were available for all scheduled visits with no history of serogroup B meningococcal 9 
vaccination, meningococcal disease or contact with it, significant infection of any nature within 10 
the previous seven days, or use of antibiotics within 72 hours of enrolment. Pregnant women, 11 
nursing mothers, females of childbearing age who did not use acceptable birth control, people 12 
with chronic disease, impairment/alteration of the immune system (including 13 
immunosuppressive therapy), or history of severe allergic reactions after vaccinations were 14 
excluded. 15 
Interventions 16 
Subjects were randomised to three arms – controls, 4CMenB and MenACWY-CRM groups. The 17 
control group received two doses of Japanese encephalitis vaccine (IXIARO® [Intercell, Vienna, 18 
Austria]). The 4CMenB group received two doses of recombinant MenB vaccine (Bexsero®; 19 
NVS). The MenACWY-CRM group received one dose of MenACWY-CRM vaccine (Menveo®; 1 
NVS) then a dose of placebo (containing 1·5 mg aluminium hydroxide) one month later.  2 
Subjects were observed for 30 minutes after each vaccination for any immediate reactions. 3 
Subjects recorded adverse events (AEs) and serious AEs (SAEs) via a paper diary throughout the 4 
study. All AEs and SAEs were judged by an investigator as not related, possibly related, or 5 
probably related to study vaccination. A subset of subjects in each group recorded solicited 6 
local and systemic reactions, as well as other indicators of reactogenicity (i.e. use of analgesic or 7 
antipyretic), via a separate paper diary for a seven day period following each vaccination.  8 
From study Day 1 to study termination there were six clinic visits over 12 months. All subjects 9 
had oropharyngeal swabs collected at every visit. N meningitidis-positive samples were 10 
identified by culture and biochemical confirmation. Isolates were further characterised by 11 
genogroups, serogroups and sequence types. Isolates were serogrouped and reported here as 12 
combined or individual serogroups. All non-serogroupable meningococci were then assessed by 13 
PCR
14
 and reported here as combined or individual capsular (caps) groups. CapsB isolates were 14 
classified into sequence types (STs) by multilocus sequence typing and reported here as strains 15 
that belong to STs associated with invasive disease in the UK, or all STs. Strains that were 16 
͚disease assoĐiated͛ ǁeƌe pƌe-defined in the analysis plan as those with matching ST or clonal 17 
complex to those found to cause invasive disease in the UK between 2006 and 2010.  18 
Outcomes 1 
The primary outcomes were carriage prevalence of (1) capsB strains belonging to STs associated 2 
with invasive disease one month after the two-dose series of either 4CMenB or control 3 
vaccination, and (2) serogroup ACWY strains at one month after a single dose of MenACWY-4 
CRM or control vaccination. 5 
Predefined secondary outcomes included: assessment of vaccine impact on carried 6 
meningococcal strains, including all capsular group ABCWY (capsABCWY) strains and all capsB 7 
strains; assessment of vaccine impact across multiple aggregate timepoints and impact on new 8 
acquisition of meningococcal strains; and assessment of vaccine impact on carriage in students 9 
with known risk factors for high transmission – younger subjects, smokers, and subjects 10 
enrolling early in the university year. A group-unblinded interim analysis was performed after 11 
all subjects had completed their third study visit.   12 
The study required 850 evaluable subjects/arm (assuming 15% drop-out rate) and a carriage 13 
pƌeǀaleŶĐe of ≥ϮϬ% foƌ eaĐh of the pƌiŵaƌǇ outĐoŵes to haǀe suffiĐieŶt poǁeƌ ;ϴϵ% eaĐh 14 
outcome) to detect a 30% relative difference in carriage prevalence. Calculations were 15 
performed with NQuery version 6·01 (two group continuity corrected chi-square test, two-sided 16 
alpha=0·05).  17 
Safety assessments included the incidence of selected indicators of reactogenicity reported 18 
within a seven-day period following each vaccination, as well as the incidence of unsolicited AEs 19 
and SAEs reported throughout the study period.  20 
Randomisation and masking 1 
Subjects were randomised in a 1:1:1 ratio into three arms using a validated computer-2 
generated random allocation list provided by NVS. Fourteen enrolled subjects were not 3 
randomised to any of the arms due to protocol deviations; these subjects did not receive any 4 
study vaccinations. To maintain study masking, subjects and investigative site personnel were 5 
blinded to group assignment until the conclusion of the study. Study vaccines were prepared 6 
and administered by unblinded personnel who did not participate in any outcome assessments; 7 
study vaccines were prepared out of the view of subjects and those persons assessing 8 
outcomes. Unblinding of subjects following completion of visit five was permitted for those 9 
individuals who required immunizations for travel to JE- or MenACWY-endemic areas. 10 
Statistical methods 11 
Analysis of pharyngeal carriage was performed on the modified intention-to-treat (MITT) 12 
population, which included all enrolled subjects who received a study vaccination and provided 13 
at least one evaluable swab sample after baseline. The percentage of subjects with N 14 
meningitidis carriage and the associated 95% Clopper-Pearson confidence intervals (CIs) were 15 
tabulated by vaccine group and timepoint. Differences between vaccine and control groups 16 
ǁeƌe aŶalǇsed usiŶg PeaƌsoŶ͛s Đhi-sƋuaƌe test oƌ Fisheƌ͛s eǆaĐt test, ǁheƌe appƌopƌiate. The 17 
percentage of subjects with new acquisition of N meningitidis carriage was calculated with two-18 
sided 95% CI for each vaccine group and at each timepoint following vaccination. New 19 
acquisition of N meningitidis carriage was defined as the detection of an N meningitidis isolate 20 
that was undetected at baseline, once the subject received at least one dose of vaccine. The 21 
odds ratios (ORs) of carriage at each visit were analysed by logistic regression, incorporating 1 
carriage status at baseline as a covariate for any post-baseline visit analyses; ORs, as measures 2 
of relative rates in the vaccine groups compared to the control group were calculated and the 3 
associated two-sided 95% CIs computed. The ORs of carriage for aggregate post-baseline visits 4 
were analysed using a generalised estimating equation (GEE) including baseline carriage status 5 
and significant risk factors as covariates. ORs and the associated two-sided 95% CIs were 6 
computed. Carriage reduction was calculated for the comparisons as (1 – OR) multiplied by 100. 7 
The duration of carriage/new acquisition was calculated by least square means (LSM) returned 8 
from a general linear model assuming normal-scale distribution of data; between group 9 
differences were adjusted by centre and group. 10 
Role of the funding source  11 
This investigator-initiated trial was funded, administered, and monitored by 12 
employees/representatives of NVS. The chief investigators drafted and then finalised the 13 
manuscript with editorial assistance funded by NVS. All authors reviewed and approved the 14 
final version. RCR, PMD, and R Borrow had full access to study data and hold final responsibility 15 
for publication submission.  16 
17 
Results 1 
Overall, 2968 subjects were enrolled (21 September to 21 December 2010) and 2954 were 2 
randomised (figure 1). The demographic variables and baseline N meningitidis carriage rates 3 
were balanced across the treatment groups (table 1). No serogroup A N meningitidis was 4 
detected in any individual. Over 99% of the randomised subjects were included in the MITT 5 
analysis. 6 
Control group characteristics 7 
At study entry, 31% (303/986) of control subjects were nasopharyngeal carriers of N 8 
meningitidis (table 1). Among control subjects with swabs from all six study visits who were 9 
negative at baseline, monthly acquisition of N meningitidis was 18% (112/627) during the first 10 
month, declining to 2% (14/361 over 6 months) at month 12. (figure 2; supplementary table 1). 11 
Acquisition of any capsulated meningococci (capsBCWY) occurred in 10% (69/663) of non-12 
carriers during the first month with lower rates thereafter. Acquisition was lowest for capsB, 13 
with 4% (26/715) acquiring within the first month of enrolment and low rates over subsequent 14 
visits (figure 2). 15 
The mean duration of any meningococcal carriage in the control group was 202 (95% CI: 185–16 
219) LSM days for all N meningitidis, 147 (95%CI: 113–182) LSM days for capsB, and 113 (95% 17 
CI: 87–138) LSM days for serogroups CWY (supplementary table 3).  18 
Impact of 4CMenB vaccination 1 
Overall carriage prevalence 2 
One month following the second vaccination (primary endpoint) there was no significant 3 
difference between the 4CMenB and control groups in the prevalence of carriage of disease-4 
associated STs of capsB (OR [95% CI], 1·2 [0·8−1·7]) (table 2). Considering all sampling points 5 
together from three months after second vaccination, there was no significant difference 6 
between the 4CMenB and control groups in carriage prevalence for all capsB (OR [95% CI]; 0·8 7 
[0·6–1·1]) or disease-associated STs of capsB (OR [95% CI]; 0·9 [0·7–1·2]) (table 3). Significantly 8 
lower carriage prevalence was, however, observed for 4CMenB versus control group at any 9 
timepoint from three months after the second vaccination (visits 4–6) for all N meningitidis, 10 
capsBCWY, capsCWY, and serogroup CWY (table 3). 11 
Acquisition, loss and duration of carriage in 4CMenB vaccinees 12 
For the aggregate timepoint (visits 4–6), there was a non-significant trend toward lower 13 
acquisition of any N meningitidis, capsBCWY, and capsB in 4CMenB-vaccinated individuals, 14 
resulting in carriage reductions of 22.3% [95% CI: -5·Ϯ− ϰϮ·6%], 15·9% [95% CI: -17·ϯ− ϯϵ·8%], 15 
and 28·6% (95% CI: -ϭϮ−ϱϰ·4%), respectively (table 4). Acquisition at individual timepoints is 16 
shown in supplementary table 1. There was no observed impact on the proportion of subjects 17 
losing carriage of all N meningitidis, capsBCWY, or capsB at any timepoint from three months 18 
after second vaccination (data not shown).  19 
Duration of carriage of any N meningitidis strains was comparable in 4CMenB and control 1 
groups (193 [95% CI: 176–210] and 202 [95% CI: 185–219] LSM days, respectively) but the 2 
4CMenB group showed a trend towards lower duration of carriage of capsBCWY (143 [95% CI: 3 
122–164] LSM days versus 162 [95% CI: 141–183] LSM days in control group), and all capsB (127 4 
[95% CI: 92–162] LSM days versus 146 [95% CI: 112–180] LSM days in control group) than the 5 
control group (supplementary table 3). 6 
High risk groups  7 
When assessed at any timepoint from three months after the second vaccination, there were 8 
significantly lower carriage rates of all N meningitidis strains in the 4CMenB group when they 9 
had received their first vaccination <30 days after the start of the university term (OR [95% CI]; 10 
0·7 [0·5–0·9]), if they were smokers (OR [95% CI]; 0·7 [0·5–1·0]) and if they were aged <21 years 11 
(OR [95% CI]; 0·8 [0·6–0·9]), (supplementary table 4). Similar findings were observed for 12 
capsBCWY (supplementary table 4). No significant difference in carriage rates was observed for 13 
these high-risk groups for capsB, including disease-associated STs.  14 
Impact of MenACWY-CRM vaccination 15 
Overall carriage prevalence 16 
At one month following vaccination there was no significant difference between the 17 
MenACWY-CRM and control groups in the prevalence of carriage of serogroups CWY 18 
(combined) (OR [95% CI]; 0·9 [0·6–1·3]) (table 2). Taking all timepoints together after two 19 
months, significantly lower carriage rates were observed in the MenACWY-CRM group 20 
compared with controls for all capsular and serogroups evaluated (table 5). The carriage 1 
reductions ranged from 36·2% (95% CI: 15·6-51·7) for serogroups CWY to 39% (95% CI: 17·3–2 
55·0) for serogroup Y (table 5). 3 
Acquisition, loss and duration of carriage  4 
From two months after one dose of MenACWY-CRM, there was a trend but no statistically 5 
significant differences towards lower acquisition rates for serogroups CWY and serogroup Y in 6 
the MenACWY-CRM group than the control group (14·8% [95% CI: -ϮϮ·ϳ−ϰϬ·ϵ%] aŶd Ϯϯ% [ϵϱ% 7 
CI: -ϭϰ·ϲ−ϰϴ·ϯ%] Đaƌƌiage ƌeduĐtioŶ, ƌespeĐtiǀelǇͿ ;taďle ϲͿ. NotaďlǇ, the MeŶACWY-CRM group 8 
had a significantly lower acquisition rate of serogroup Y than the control group (66·7% carriage 9 
reduction) at two months after one dose of MenACWY-CRM (data not shown). Acquisition at 10 
individual timepoints is shown in supplementary table 2.   11 
A trend towards lower duration of carriage was observed in the MenACWY-CRM vaccination 12 
group compared with control for serogroups CWY (vaccination: 88 [95% CI: 62–114] LSM days; 13 
control: 113 [95% CI: 87–138] LSM days) and serogroup Y (vaccination: 86 [95% CI: 59–114] LSM 14 
days; control: 117 [95% CI: 91–144] LSM days; supplementary table 5). Similarly, the 15 
MenACWY-CRM vaccinated group showed a trend to lower duration of carriage compared with 16 
the control group for newly acquired serogroups CWY (vaccination: 90 [95% CI: 57–123] LSM 17 
days; control: 120 [95% CI: 89–151] LSM days) and serogroup Y (vaccination: 87 [95% CI: 52–18 
122] LSM days; control: 120 [95% CI: 87–153] LSM days; supplementary table 5) strains. 19 
High risk groups  1 
In subjects at higher risk of carriage, the MenACWY group showed significantly lower carriage 2 
rates of serogroups CWY and serogroup Y among early vaccinated subjects (OR [95% CI]; 0·5 3 
[0·3–0·8] for serogroups CWY; OR [95% CI]; 0·6 [0·4–1·0] for serogroup Y) and subjects aged <21 4 
years (OR [95% CI]; 0·7 [0·5–1·0] for serogroups CWY; OR [95% CI]; 0·7 [0·5–1·0] for serogroup 5 
Y; supplementary table 6). No significant difference was observed among smokers.  6 
Reactogenicity and safety 7 
Of 2968 subjects enrolled in the study, 2943 (99%) were exposed to at least one study 8 
vaccination and contributed to the safety analyses. Solicited local and systemic reactions 9 
occurring within the seven-day period following each vaccination were analysed in a subset of 10 
subjects in each group (4CMenB, n=185 (19%); MenACWY-CRM: n=176 (18%); Control: n=182 11 
(18%)). Rates of solicited local reactions after any vaccination were generally higher in the 12 
4CMenB group, with overall lower reports of reactogenicity following the second vaccination as 13 
compared to the first vaccination within this group (supplementary table 7). Rates of solicited 14 
systemic reactions after any vaccination were similar across groups, with exception to myalgia, 15 
which was reported at a higher rate in the 4CMenB group. Across groups, the most commonly 16 
reported local and systemic reactions were injection site pain and myalgia, respectively. 17 
Overall, there was a low incidence of severe reactions across all groups.  18 
The incidence of unsolicited AEs after any vaccination in the overall safety set were similar 19 
across groups (35-40%), with a majority of these AEs assessed as unrelated study vaccination 20 
(supplementary table 8). For the study duration, the most commonly reported unsolicited AEs 1 
across groups were tonsillitis (3%) and urinary tract infection (2-3%). Across vaccine groups, a 2 
similar rate (2-3%) of subjects reported SAEs, with three subjects in the 4CMenB group 3 
reporting SAEs that were judged as at least possibly related to the study vaccine (dyspnoea, 4 
hand tremors, and acute thyroiditis occurring 2, 18, and 18 days post-vaccination, respectively). 5 
Premature withdrawals due to AEs were reported by 1% of subjects across vaccine groups. 6 
Discussion 7 
Over the one year period of follow-up, the MenACWY-CRM and 4CMenB vaccines significantly 8 
reduced carriage of N meningitidis. MenACWY-CRM impacted on carriage of vaccine serogroups 9 
whilst 4CMenB had a broad effect. The latter impact is not surprising, as although 4CMenB is 10 
ĐhaƌaĐteƌized as a ͞MeŶB ǀaĐĐiŶe,͟ aŶtigeŶs ĐoŶtaiŶed iŶ the ǀaĐĐiŶe aƌe pƌeseŶt iŶ, aŶd aďle 11 
to induce bactericidal antibodies against, non-serogroup B strains as well.
15
 However, neither 12 
vaccine exhibited any immediate impact on carriage one month after completion of the vaccine 13 
course, nor was the study able to demonstrate a specific impact of 4CMenB on carriage of 14 
capsB strains.  15 
Evaluations in other clinical trials or early post-implementation studies after glycoconjugate 16 
vaccines have revealed positive effects on reduction of carriage several months or even years 17 
after vaccination.
16–19
 As such, it is not clear whether the lack of significant difference after 18 
one month is unusual or, more likely, too early to accumulate sufficient acquisition events to 19 
demonstrate an impact. Post-glycoconjugate vaccination evaluations of pneumococcal carriage 20 
similarly did not show any early impact and only at later timepoints were differences 1 
demonstrated. 
20,21
 2 
For MenACWY-CRM, significantly lower carriage rates were observed for serogroups CWY 3 
(36·2% carriage reduction) and serogroup Y (39·0% carriage reduction) specifically when 4 
assessed at any timepoint from two months after vaccination. Evaluation of acquisition of 5 
serogroups CWY and serogroup Y carriage suggests that the lower carriage rates result mainly 6 
from reduction in acquisition rather than increased carriage clearance among vaccinated 7 
individuals compared with controls. This is expected and consistent with results from other 8 
carriage studies where impact on acquisition is thought to be the mechanism by which vaccine-9 
induced responses may impact on overall carriage. Reduction in carriage has been observed 10 
with a range of glycoconjugate vaccines including different pneumococcal vaccines, serogroup 11 
A and C meningococcal vaccines, and a Haemophilus influenzae type b vaccine (Hib).
18,22–27
  12 
Similarly, although 4CMenB vaccination did not result in a significant reduction in carriage 13 
prevalence for capsB one month after vaccination, significant differences in carriage of N 14 
meningitidis, capsBCWY, capsCWY, serogroups CWY, capsY, and serogroup Y (18·2–29·6% 15 
carriage reduction) were observed when assessed at any timepoint from three months after 16 
second vaccination. Evaluations of impact of 4CMenB on specific STs associated with serogroup 17 
B (e.g., ST-41/44, ST32, ST269) did not reveal differences between groups although numbers of 18 
isolates were very small, which limits interpretation (data not shown). Whilst the effect of 19 
4CMenB on disease–associated meningococci may contribute to herd protection, the potential 20 
broad additional effect on commensal Neisseria and non-disease-associated N meningitidis 21 
cannot be predicted. Significant effects on carriage were observed both across the whole 1 
student population and also across sub-populations where acquisition rates are known to be 2 
highest, such as in smokers, early enrollers and younger students.  3 
In 1999 the UK introduced MenC conjugate vaccination to all persons younger than 18 years, 4 
rapidly achieving a high coverage rate. Based on analyses of disease rates in unvaccinated 15–5 
17 year olds before and after vaccine introduction, herd protection was quantified at 67% after 6 
one year,
28
 increasing to 75% after two years, with an observed disproportionately high impact 7 
on carriage of the genotype associated with the UK epidemic in the 1990s.
18
 Although the 8 
observed carriage impact in the present study appears modest, in the setting of a pathogen 9 
such as N meningitidis, with a relatively low estimated basic reproduction number (R0 ~ 1·36),
29
 10 
even a modest individual carriage impact may translate into a significant level of herd 11 
protection. 12 
There are some limitations to the work described here. There was limited new acquisition of 13 
meningococcal strains, and in particular capsB strains, across the one year of study follow-up. It 14 
is generally agreed that glycoconjugate vaccines impact carriage through decreasing new 15 
acquisition and not eliminating existing carriage. As 4CMenB is a two-dose series and the 16 
highest acquisition was observed between the first two study visits, and because enrolment 17 
took place over a three month period, vaccines may have been administered too late to 18 
observe a maximal impact. Carriage among the university students in our study is consistent 19 
with others, with a peak during the late teenage years.
4
 Thus, for greatest impact, a vaccine 20 
programme might be initiated among early teens rather than university students as in this 1 
study. 2 
We observed that both 4CMenB and MenACWY-CRM were generally well-tolerated, with no 3 
indications of safety concerns. While reactogenicity following any vaccination was overall 4 
higher in the 4CMenB group, the incidence of unsolicited AEs was similar across groups 5 
throughout the study period. Moreover, the rates of SAEs were low and similar across all 6 
vaccine groups.    7 
In summary, results from pre-specified secondary analyses of this study support the conclusion 8 
that both MenACWY-CRM and 4CMenB have an impact on carriage and could provide a degree 9 
of herd protection against meningococcal disease if implemented in a campaign targeting a 10 
population (e.g., adolescents) where high transmission is known to occur. Although the study 11 
was not designed to provide precise estimates of herd protection, an estimate of individual 12 
carriage impact of 27% for 4CMenB (based on data from capsBCWY) and 36% for MenACWY-13 
CRM (based on data from serogroup CWY) assumptions can be made; the impact of 4CMenB on 14 
capsB strains is less clear. An appropriate translation of this individual carriage impact estimate 15 
into herd protection will likely only be available after implementation of large scale vaccination 16 
programmes. 17 
Panel: Research in Context 18 
Systematic review 19 
In addition to direct protection, the ability of a meningococcal vaccine to impact colonization and 1 
transmission of meningococci and, in turn, to provide indirect protective effects through herd 2 
protection, has important implications for evaluating the population impact and cost effective benefit of 3 
the vaccine. We seaƌĐhed PuďMed ǁith the Me“H teƌŵs ͞Neisseƌia͟ AND ͞ǀaĐĐiŶe͟ AND ͞ƌaŶdoŵized 4 
ĐoŶtƌolled tƌial͟ AND ͞iŵpaĐt͟ O‘ ͞eǀaluatioŶ͟ O‘ ͞effeĐtiǀeŶess͟ to fiŶd papeƌs puďlished ďetǁeeŶ 5 
1970 (when meningococcal polysaccharides vaccines were first investigated) and March 19
th
 2014, that 6 
reported randomised controlled trials which investigated  oropharyngeal carriage in human recipients of 7 
meningococcal vaccines. We searched Web of Science for articles that cited selected references. No 8 
such randomised controlled trials were identified, and no studies have previously investigated the effect 9 
of non-polysaccharide vaccines on meningococcal colonisation. Incorporation of monovalent 10 
meningococcal conjugate vaccines against serogroup C and serogroup A in mass vaccination 11 
programmes in the United Kingdom and sub-Saharan Africa, respectively, has resulted in significant 12 
reduction of cross-sectional pharyngeal carriage rates  of the respective serogroup in those targeted 13 
populations;
18,27,28,30
 however, the impact of vaccination with a quadrivalent meningococcal vaccine or a 14 
protein-based meningococcal vaccine such as 4CMenB on pharyngeal meningococcal carriage has not 15 
yet been clinically evaluated .
5, 10
  16 
 17 
Interpretation 18 
This is the first randomised controlled trial of oropharyngeal carriage rates of Neisseria meningitidis 19 
after meningococcal vaccination. These data suggest that 4CMenB or MenACWY-CRM are likely to 20 
provide individual protection against the acquisition of carriage of meningococci when evaluated over a 21 
broad time window after vaccination, and the scale of the effect can be used to aid in estimates of cost-22 
effectiveness.  This study was conducted in the United Kingdom in a population sub-group – young 23 
adults – with high rates of Đaƌƌiage aŶd tƌaŶsŵissioŶ, iŶ oƌdeƌ to pƌoǀide a ͞pƌoof of pƌiŶĐiple͟ that these 24 
vaccines may provide herd protection, and data to guide implementation decisions wherever they may 1 
be made. 2 
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Table 1: Demographics, baseline characteristics and carriage 
 4CMenB MenACWY-CRM Control Total 
 N=979 N=988 N=987 N=2968
†
 
Age (Years±SD) 19·9±1·6 
(N=977) 
19·9±1·6 19·8±1·6 
19·9±1·6 
(N=2966) 
Males, n (%) 
 
463 (47) 455 (46) 440 (45) 1369 (46) 
Caucasian, n (%) 
 
860 (88) 876 (89) 866 (88) 2610 (88) 
Weight (kg±SD) 69·7±13·2 
(n=973) 
68·8±13·4 
(n=985) 
69·2±13·5 
(n=986) 
69·2±13·4 
(n=2950) 
Height (cm±SD) 172·6±9·4 
(n=974) 
172·5±9·4 
(n=987) 
172·0±9·4 
(n=986) 
172·4±9·4 
(n=2953) 
Smokers, n/N (%)* 
 
159/974 (16) 161/983 (16) 143/984 (15) 463/2941 (16) 
Carriage, n (%) N=976 N=984 N=986 N=2946 
N meningitidis 326 (33) 334 (34) 303 (31) 963 (33) 
   A (serogroupable) 0 (0) 0 (0) 0 (0) 0 (0) 
   B (all) 92 (9) 100 (10) 86 (9) 278 (9) 
   B (disease-associated) 78 (8) 84 (9) 72 (7) 234 (8) 
   B (all serogroupable) 66 (7) 73 (7) 57 (6) 196 (7) 
   C (all) 3 (0) 3 (0) 3 (0) 9 (0) 
   C (serogroupable) 1 (0) 1 (0) 0 (0) 2 (0) 
   W (all) 20 (2) 20 (2) 10 (1) 50 (2) 
   W (serogroupable) 15 (2) 15 (2) 4 (0) 34 (1) 
   Y (all) 70 (7) 67 (7) 68 (7) 205 (7) 
   Y (serogroupable) 54 (6) 42 (4) 45 (5) 141 (5) 
   CWY (all) 93 (10) 90 (9) 81 (8) 264 (9) 
   CWY (serogroupable) 70 (7) 58 (6) 49 (5) 177 (6) 
 N lactamica 7 (1) 5 (1) 5 (1) 17 (1) 
*Number and percentage of smokers are from Day 1 visit. †Total includes the 14 enrolled subjects who were not 
randomised; the number of subjects for each site were as follows: Univ. of Sheffield Medical School (n=826); St. Georges 
Hospital (n=156); Nottingham University Hospital / NHS (n=319); Oxford Vaccine Group (n=263); South Tees Hospital 
Foundation (n=121); University of Manchester (n=255); Liverpool School of Tropical Medicine (n=501); University of 
Southampton (n=308); North Bristol NHS Trust (n=206); University of Surrey (n=13).  
Table 2: Pharyngeal carriage prevalence of disease-associated STs of capsB in 4CMenB and 
control groups and serogroups A, C, W or Y (combined) of N meningitidis in MenACWY-
CRM and control groups (primary endpoints; MITT Population) 
 Percentage of subjects with 
carriage  
n/N (%; 95% CI) 
Group 
difference % 
(95% CI)*
 
OR 
(95% CI) 
Carriage 
Reduction,
†
 
% (95% CI) 
 4CMenB 
(N=974) 
Control  
(N=984) 
   
Day 1 (Baseline) 78/974  
(8; 6–10) 
72/984  
(7; 6–9) 
0.6 
;−ϭ·ϲ–2·7) 
 NA NA 
1 month after 
2
nd
 vaccination 
87/916  
(9; 8–12) 
 
75/928  
(8; 6–10) 
1·0 
;−ϭ·ϱ–3·5) 
1·2 
(0·8–1·7) 
−ϭϴ·Ϯ 
;−ϳϯ·ϯ–19·4) 
 MenACWY-
CRM (N=981) 
Control  
(N=984) 
   
Day 1 (Baseline) 58/981  
(6; 5–8) 
49/984  
(5; 4–7) 
0 
;−Ϭ·ϰ–0·4) 
NA NA 
1 month after 
vaccination 
57/956  
(6; 5–8) 
 
58/947  
(6; 5–8) 
 
−ϭ 
;−Ϯ·ϴ–0·8) 
0·9 
(0·6–1·3) 
10·5  
;−ϯϰ·Ϯ–40·3) 
*Vaccine group differences in proportions between vaccine and control groups were analyzed by using 
PeaƌsoŶ͛s Đhi-sƋuaƌe test oƌ Fisheƌ͛s eǆaĐt test ǁheƌe appƌopƌiate ǁith ĐeŶteƌ aŶd tƌeatŵeŶt gƌoup iŶ the 
model. 
†
Carriage Reduction = 100 × (1-OR)  
NA=Not applicable 
Table 3: Odds Ratios (GEE model) for carriage prevalence of N meningitidis in 4CMenB and 
control groups at any timepoint from three months after second vaccination (visits 4 to 6) 
– MITT population  
 Percentage of positive 
samples, n (%) 
OR 
(95% CI) 
Carriage 
Reduction,
†
 % 
(95% CI) 
 4CMenB 
N=2489 
Control 
N=2576 
  
All STs of capsB 233 (9·4) 
 
262 (10·2) 
 
0·8 
(0·6–1·1) 
15·6% 
;−ϭϭ·Ϭ–35·9) 
Disease-associated 
STs of capsB 
214 (8·6) 
 
237 (9·2) 
 
0·9 
(0·7–1·2) 
12·6% 
;−ϭϱ·ϵ–34·1) 
All N meningitidis 797 (32·0) 
 
885 (34·4) 
 
0·8 
(0.7–1.0) 
18·2% 
(3.4–30.8) 
Capsular groups 
BCWY 
449 (18·0) 
 
539 (20·9) 
 
0·7 
(0·6–0·9) 
26·6% 
(10·5–39·9) 
Capsular groups 
CWY 
216 (8·7) 
 
277 (10·8) 
 
0·7 
(0·5–0·9) 
29·6% 
(8·1–46·0) 
Serogroups CWY 149 (6) 
 
186 (7·2) 
 
0·7 
(0·5–1.0) 
28·5% 
(2·8–47·5) 
Capsular Y 178 (7·2) 
 
228 (8·9) 
 
0·7 
(0·6–1·0) 
25·1% 
;−Ϭ·Ϯ–44·0) 
Serogroup Y 128 (5·1) 
 
161 (6·3) 
 
0·7 
(0·5–1·0) 
28·2% 
;−Ϭ·ϭ–48·4) 
͞N͟ giǀeŶ foƌ GEE ƌesults ƌefeƌs to total Ŷuŵďeƌ of sǁaď saŵples aĐƌoss ǀisits. 
OR and Carriage Reduction adjusted by treatment group, baseline status, and significant risk factors as 
identified within the multivariate model 
 
†
Carriage Reduction = 100 × (1-OR).   
Table 4: Percentage of subjects with new acquisition of pharyngeal carriage at 3, 5 or 11 months post second vaccination with 4CMenB 
versus controls (Pharyngeal carriage; subjects with all 6 swabs)  
 Percentage of subjects with 
carriage  
n/N (%; 95% CI) 
Difference between 
Vaccine Groups (95% CI) 
Odds Ratio 
(95%CI) 
Carriage Reduction, % 
(95% CI) 
 4CMenB  Control 4CMenB   
Any N meningitidis 105/410  
(26; 21–30) 
 
140/452  
(31; 27–35) 
 
−ϱ% 
;−ϭϭ%–1%) 
0·8 
(0·6–1·1) 
22·3% 
;−ϱ·Ϯ%–42·6%) 
Capsular groups, BCWY 74/519  
(14; 11–18) 
 
91/551  
(17; 14–20) 
 
−Ϯ% 
;−ϳ%–2%) 
0·8 
(0·6–1·2) 
15·9% 
;−ϭϳ·ϯ%–39·8%) 
All capsB 34/628  
(5; 4–7) 
 
50/674  
(7; 6–10) 
 
−Ϯ% 
;−ϱ%–1%) 
0·7 
(0·5–1·1) 
28·6% 
;−ϭϮ·0%–54·4%) 
Disease-associated capsB 34/638  
(5; 4–7) 
 
44/686  
(6; 5–9) 
−ϭ% 
;−ϰ%–1%) 
0·8 
(0·5–1·3) 
17·9% 
;−ϯϬ·ϯ%–48·2%) 
OR and Carriage Reduction adjusted by treatment group, baseline status, and significant risk factors as identified within the multivariate model 
  
Table 5: Odds Ratios (GEE Model) for carriage prevalence of N meningitidis in MenACWY-
CRM and control groups at any timepoint after two months of one vaccine dose (Visits 3 
to 6) (MITT Population) 
 Percentage of positive samples OR 
(95% CI) 
Carriage Reduction, % 
(95% CI) 
 MenACWY-CRM  
n (%) 
N=3520 
Control 
n (%) 
N=3504 
  
Capsular CWY 333 (9·5) 
 
388 (11·1) 
 
0·7 
(0·6–0·9) 
27·1 
(6·9–42·9) 
Serogroups CWY 193 (5·5) 
 
260 (7·4) 
 
0·6 
(0·5–0·8) 
36·2 
(15·6–51·7) 
Capsular Y 261 (7·4) 
 
325 (9·3) 
 
0·7 
(0·6–1·0) 
26·5 
(4·1–43·7) 
Serogroup Y 157 (4·5) 
 
227 (6·5) 
 
0·6 
(0·5–0·8) 
39·0 
(17·3–55·0) 
͞N͟ giǀeŶ foƌ GEE ƌesults ƌefeƌs to total Ŷuŵďeƌ of sǁaď saŵples aĐƌoss ǀisits. 
OR and Carriage Reduction adjusted by treatment group, baseline status, and significant risk factors 
as identified within the multivariate model 
 
  
Table 6: Percentage of subjects with new acquisition of pharyngeal carriage at 2, 4, 6 or 12 
months post first dose/1, 3, 5 or 11 months post second vaccination with MenACWY-CRM 
versus controls (Pharyngeal carriage; subjects with all 6 swabs)  
 
 Percentage of subjects with 
carriage  
n/N (%; 95% CI) 
Difference 
between Vaccine 
Groups (95% CI) 
Odds Ratio 
(95%CI) 
Carriage 
Reduction 
 MenACWY-CRM Control    
Serogroups CWY 59/712  
(8; 6-11) 
 
68/709  
(10; 8-12) 
 
−1% 
;−ϰ%-2%) 
0·9 
(0·6-1·2) 
14·8% 
;−ϮϮ·7%-
40·9%) 
Serogroup Y 47/730  
(6; 5-8) 
 
59/719  
(8; 6-10) 
 
−2% 
;−ϱ%-1%) 
0·8 
(0·5-1·2) 
23·0% 
;−ϭϰ·6%-
48·3%) 
OR and Carriage Reduction adjusted by treatment group, baseline status, and significant risk factors as 
identified within the multivariate model 
 
